CNBC: Moderna reports positive data on early-stage coronavirus vaccine trial, shares surge
Moderna said its early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all participants, sending its shares surging.
This trial was performed on a small group of people between the ages of 18 to 55.
Early results from Moderna’s coronavirus vaccine trial show participants developed antibodies against the virus. This comes from a Phase 1 clinical trial. The information has neither been peer reviewed nor published in a medical journal.https://t.co/2PIl4m13ZV pic.twitter.com/zLVI4Evx8w
— CNN This Morning with Kasie Hunt (@CNNThisMorning) May 18, 2020
